ZYMEWORKS INC. Net Income
ZYMEWORKS INC. (ZYME) reported Net Income of -$45.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- ZYMEWORKS INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$45.02M, a 2042.99% decline year-over-year.
- ZYMEWORKS INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$44.16M.
- ZYMEWORKS INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$41.21M.
- ZYMEWORKS INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$19.60M.
- ZYMEWORKS INC. net income (loss) attributable to parent for fiscal 2025 was -$81.13M.
- ZYMEWORKS INC. net income (loss) attributable to parent for fiscal 2024 was -$122.69M.
- ZYMEWORKS INC. net income (loss) attributable to parent for fiscal 2023 was -$118.67M, a 195.44% decline from fiscal 2022.
- ZYMEWORKS INC. net income (loss) attributable to parent for fiscal 2022 was $124.34M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$45.02M 10-Q · filed 2026-08-06 | -$89.18M 10-Q · filed 2026-08-06 | -$130.39M derived: sum of 3 quarters · filed 2026-08-06 | -$149.99M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$44.16M 10-Q · filed 2026-08-06 | -$85.37M derived: sum of 2 quarters · filed 2026-08-06 | -$104.97M derived: sum of 3 quarters · filed 2026-08-06 | -$102.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$41.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$60.81M derived: sum of 2 quarters · filed 2026-03-02 | -$58.49M derived: sum of 3 quarters · filed 2026-08-06 | -$81.13M 10-K · filed 2026-03-02 |
| 2025-09-30 | -$19.60M 10-Q · filed 2025-11-06 | -$17.29M derived: sum of 2 quarters · filed 2026-08-06 | -$39.92M 10-Q · filed 2025-11-06 | -$63.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.32M 10-Q · filed 2026-08-06 | -$20.32M 10-Q · filed 2026-08-06 | -$43.83M derived: sum of 3 quarters · filed 2026-08-06 | -$73.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$22.64M 10-Q · filed 2026-08-06 | -$46.14M derived: sum of 2 quarters · filed 2026-08-06 | -$75.99M derived: sum of 3 quarters · filed 2026-08-06 | -$113.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$23.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$53.36M derived: sum of 2 quarters · filed 2026-03-02 | -$91.04M derived: sum of 3 quarters · filed 2026-03-02 | -$122.69M 10-K · filed 2026-03-02 |
| 2024-09-30 | -$29.85M 10-Q · filed 2025-11-06 | -$67.54M derived: sum of 2 quarters · filed 2025-11-06 | -$99.19M 10-Q · filed 2025-11-06 | -$113.67M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | -$37.69M 10-Q · filed 2025-11-06 | -$69.34M 10-Q · filed 2025-08-07 | -$83.82M derived: sum of 3 quarters · filed 2026-03-02 | -$112.51M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | -$31.65M 10-Q · filed 2025-11-06 | -$46.13M derived: sum of 2 quarters · filed 2026-03-02 | -$74.82M derived: sum of 3 quarters · filed 2026-03-02 | -$125.97M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | -$14.48M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | -$43.17M derived: sum of 2 quarters · filed 2026-03-02 | -$94.32M derived: sum of 3 quarters · filed 2026-03-02 | -$118.67M 10-K · filed 2026-03-02 |
| 2023-09-30 | -$28.69M 10-Q · filed 2024-10-31 | -$79.84M derived: sum of 2 quarters · filed 2024-10-31 | -$104.19M 10-Q · filed 2024-10-31 | $205.24M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-06-30 | -$51.15M 10-Q · filed 2024-10-31 | -$75.50M 10-Q · filed 2024-08-01 | $233.93M derived: sum of 3 quarters · filed 2025-03-05 | $186.08M derived: sum of 4 quarters · filed 2025-03-05 |
| 2023-03-31 | -$24.35M 10-Q · filed 2024-10-31 | $285.08M derived: sum of 2 quarters · filed 2025-03-05 | $237.23M derived: sum of 3 quarters · filed 2025-03-05 | $172.61M derived: sum of 4 quarters · filed 2025-03-05 |
| 2022-12-31 | $309.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | $261.58M derived: sum of 2 quarters · filed 2025-03-05 | $196.97M derived: sum of 3 quarters · filed 2025-03-05 | $124.34M 10-K · filed 2025-03-05 |
| 2022-09-30 | -$47.85M 10-Q · filed 2023-11-07 | -$112.47M derived: sum of 2 quarters · filed 2023-11-07 | -$185.09M 10-Q · filed 2023-11-07 | -$224.24M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | -$64.62M 10-Q · filed 2023-11-07 | -$137.24M 10-Q · filed 2023-08-10 | -$176.40M derived: sum of 3 quarters · filed 2024-03-06 | -$236.97M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | -$72.63M 10-Q · filed 2023-11-07 | -$111.78M derived: sum of 2 quarters · filed 2024-03-06 | -$172.36M derived: sum of 3 quarters · filed 2024-03-06 | -$239.88M derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | -$39.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | -$99.73M derived: sum of 2 quarters · filed 2024-03-06 | -$167.25M derived: sum of 3 quarters · filed 2024-03-06 | -$211.84M 10-K · filed 2024-03-06 |
| 2021-09-30 | -$60.58M 10-Q · filed 2022-11-08 | -$128.10M derived: sum of 2 quarters · filed 2022-11-08 | -$172.69M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | -$67.52M 10-Q · filed 2022-11-08 | -$112.11M derived: sum of 2 quarters · filed 2022-11-08 | ||
| 2021-03-31 | -$44.59M 10-Q · filed 2022-11-08 | |||
| 2020-12-31 | -$180.55M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |